Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT03040986 Completed - Clinical trials for Stage IV Pancreatic Cancer AJCC v6 and v7

Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

Start date: July 21, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or other places in the body. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03033927 Active, not recruiting - Pancreatic Cancer Clinical Trials

Predicting Effective Therapy in Pancreatic Cancer

Start date: January 24, 2017
Phase:
Study type: Observational

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

NCT ID: NCT03033225 Completed - Pancreatic Neoplasm Clinical Trials

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

Start date: December 6, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (advanced). Photodynamic therapy is a type of laser device that is guided by ultrasound imaging and used in combination with the drug verteporfin that may be less invasive and as effective as current treatment methods for patients with pancreatic cancer.

NCT ID: NCT03032913 Completed - Clinical trials for Pancreatic Ductal Adenocarcinoma (PDAC)

Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC

PANC-CTC
Start date: February 15, 2017
Phase:
Study type: Observational

The proposal aims at determining whether liquid biopsy approaches are valid in the diagnosis of pancreatic cancer. Step1 will test 3 CTC isolation methods and analyse by flow cytometry the presence of onco-exosomes in the culture media of pancreatic cell lines. Step 2 will examine the diagnostic accuracy of these blood tumor elements for the diagnosis of cancer of patients with PDAC suspicion or recent diagnosis and their value for disease monitoring.

NCT ID: NCT03023722 Completed - Pancreatic Cancer Clinical Trials

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Start date: May 11, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to: -Test the activity/response rate per RECIST 1.1 criteria of anetumab ravtansine in patients with advanced pancreatic cancer who stain for mesothelin expression The secondary objectives of this study are to: - Time to Progression (TTP) defined as time from study treatment to RECIST 1.1 progression, or death (others going off study will be censored) - Toxicity in pancreatic cancer patients (at 6.5 mg/kg dose)

NCT ID: NCT03021668 Completed - Pancreatic Cancer Clinical Trials

Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections

Start date: January 2017
Phase: N/A
Study type: Interventional

Pancreaticoduodenectomy is associated with high perioperative morbidity, with surgical site infection (SSIs) being one of the most common complications. A retrospective study at Hopkins on SSIs in these patients identified the rate of SSIs to be 16.7% and pre-operative bile stent/drain and neoadjuvant chemotherapy were independent predictors of surgical site infection. Patients with these factors having a predicted risk of up to 32%. Another subsequent retrospective study demonstrated that the use of negative pressure wound therapy device was significantly associated with a decrease in the rate of SSIs. The hypothesis of the investigator(s) for the current study is that placement of Prevena Peel & Place Dressing (Negative Pressure Wound Therapy, NPWT) in patients undergoing pancreaticoduodenectomy who are at high risk of SSIs will result in a significant decrease in their SSI rate.

NCT ID: NCT03017690 Completed - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Start date: April 12, 2017
Phase:
Study type: Observational

An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

NCT ID: NCT03017599 Completed - Pancreatic Cancer Clinical Trials

Yield Rate for Procurement the Histologic Core With Endoscopic Ultrasound-guided Fine Needle Biopsy With 20-gauge Ultrasound Biopsy Needles for Solid Pancreatic Masses: Pilot Study

Start date: July 11, 2016
Phase: N/A
Study type: Interventional

To investigate the technical feasibility and diagnostic yield of new 20-gauge Procore needle for EUS-guided fine needle biopsy in pancreatic solid lesions.

NCT ID: NCT03016637 Completed - Pancreatic Cancer Clinical Trials

Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy

PANCOBE
Start date: January 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates whether a new endoscopic ultrasonography (EUS) histology needle may improve the diagnostic yield during biopsies of pancreatic lesions

NCT ID: NCT03013712 Recruiting - Prostate Cancer Clinical Trials

A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer

CARTEPC
Start date: January 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of EpCAM-specific CAR T Cells infusion for EpCAM positive Cancer.